170 related articles for article (PubMed ID: 38057698)
1. Predictive value of CCL2 in the prognosis and immunotherapy response of glioblastoma multiforme.
Deng L; Ren J; Li B; Wang Y; Jiang N; Wang Y; Cui H
BMC Genomics; 2023 Dec; 24(1):746. PubMed ID: 38057698
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
Li H; Wang D; Yi B; Cai H; Xi Z; Lou X; Li Z
Biomed Res Int; 2021; 2021():8357585. PubMed ID: 34395626
[TBL] [Abstract][Full Text] [Related]
3. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
4. MCP-1 and MIP-3α Secreted from Necrotic Cell-Treated Glioblastoma Cells Promote Migration/Infiltration of Microglia.
Jung Y; Ahn SH; Park H; Park SH; Choi K; Choi C; Kang JL; Choi YH
Cell Physiol Biochem; 2018; 48(3):1332-1346. PubMed ID: 30048972
[TBL] [Abstract][Full Text] [Related]
5. Association between SNAP25 and human glioblastoma multiform: a comprehensive bioinformatic analysis.
Yu C; Yin J; Wang X; Chen L; Wei Y; Lu C; You Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32412599
[TBL] [Abstract][Full Text] [Related]
6. C1R, CCL2, and TNFRSF1A Genes in Coronavirus Disease-COVID-19 Pathway Serve as Novel Molecular Biomarkers of GBM Prognosis and Immune Infiltration.
Wang X; Yang G; Wang Q; Zhao Y; Ding K; Ji C; Shi Z; Li H; Li Y; Li S
Dis Markers; 2022; 2022():8602068. PubMed ID: 35726234
[TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
8. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
9. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
10. Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma.
Yan Z; Chu S; Zhu C; Han Y; Liang Q; Shen S; Cheng W; Wu A
PeerJ; 2021; 9():e12547. PubMed ID: 35036121
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
12. CCL2/CCR2 signaling pathway in glioblastoma multiforme.
Vakilian A; Khorramdelazad H; Heidari P; Sheikh Rezaei Z; Hassanshahi G
Neurochem Int; 2017 Feb; 103():1-7. PubMed ID: 28025034
[TBL] [Abstract][Full Text] [Related]
13. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype.
Lv SQ; Fu Z; Yang L; Li QR; Zhu J; Gai QJ; Mao M; He J; Qin Y; Yao XX; Lan X; Wang YX; Lu HM; Xiang Y; Zhang ZX; Huang GH; Yang W; Kang P; Sun Z; Shi Y; Yao XH; Bian XW; Wang Y
Theranostics; 2022; 12(1):459-473. PubMed ID: 34987659
[No Abstract] [Full Text] [Related]
15. Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
Bi Y; Wu ZH; Cao F
BMC Cancer; 2022 Mar; 22(1):233. PubMed ID: 35241019
[TBL] [Abstract][Full Text] [Related]
16. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma.
Zhu Z; Zhang X; Yu Z; Zhou Y; Zhu S; Zhang YH; Lin XP; Mou Y; Zhang J
J Neuroimmunol; 2021 Jun; 355():577575. PubMed ID: 33901809
[TBL] [Abstract][Full Text] [Related]
18. A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
Fan W; Wang D; Li G; Xu J; Ren C; Sun Z; Wang Z; Ma W; Zhao Z; Bao Z; Jiang T; Zhang Y
CNS Neurosci Ther; 2022 Dec; 28(12):2090-2103. PubMed ID: 35985661
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
[TBL] [Abstract][Full Text] [Related]
20. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
